The US Food and Drug Administration (FDA) has approved a drug for heart failure manufactured by Texas-based Lexicon Pharma, it was reported on Saturday.
Sotagliflozin, an oral drug, is the company's first to be approved by the US health agency. It will be sold under the brand name Inpefa. An earlier drug from the firm, which is an add-on to insulin therapy for type 1 diabetes, had failed to get US approval.
The drug is aimed at a broad treatment of heart failure diseases, including in adult patients with type 2 diabetes.
Pierre Fabre Pharmaceuticals reports FDA acceptance and Priority Review of Tabelecleucel BLA
Bavarian Nordic's chikungunya vaccine receives validation from EMA for accelerated review
Atara Biotherapeutics gains FDA Priority Review for tabelecleucel
Hyperfine secures FDA clearance for faster brain imaging software
Silo Pharma agrees Alzheimer's drug licence
Kyverna's KYV-101 granted FDA Regenerative Medicine Advanced Therapy designation
Camurus reports positive Phase 3 ACROINNOVA 2 results
Acurx Pharmaceuticals presents positive Ibezapolstat Phase 2 clinical trial results for CDI